Matthew Quinn

Manager, Analytical Development, Global Nucleic Acid Therapies at Novo Nordisk

Speaker

18yrs in Pharmaceutical sciences. The first 3yrs were in contract analytical, supporting various pharmaceutical companies in unknown analysis and ID, method development and validation. I then moved onto 5yrs in “first to file” small molecule generics at Hospira where I conducted impurity structure and elucidation, method development and analytical lead. From there I went onto Corden Pharma Boulder CO for 5yrs where I was responsible for downstream peptide purification as well as analytical development and most recently, 5yrs now with Dicerna/NovoNordisk as the analytical development lead and most recently AD Manager for highly modified Oligonucleotides.